27O Long-term survival outcomes and immune subgroup analyses in the COLIBRI study: Induction nivolumab plus ipilimumab with immunotherapy maintenance (ICB) prior to and following chemoradiation (RT-CT) in locally advanced cervical cancer (LACC)
Induction nivolumab plus ipilimumab associated with RT-CT is a promising treatment intensification strategy (Ray-Coquard et al., Nature Comm 2026) in LACC. Although immune modulation and early tumor responses have been previously reported, there is less information on survival outcomes and their relation to baseline immune parameters. Here we report the final survival outcomes of the multicenter single arm COLIBRI study, including exploratory immuno-based subgroup analyses.
Authors
- S. Betrian
- F. Lecuru
- F. Cherifi
- A. Angelergues
- A. DeMontfort
- L. Gladieff
- C. Caux
- R. Ohkuma
- M-C. Kaminsky-Forrett
- B. Dubois
- A-C. Hardy-Bessard
- D. Bello Roufai
- A. Lainé
- I. Treilleux
- Y. Fernandez Diez
- L. Michon
- F. Joly Lobbedez
- P. Saintigny
- A-M. Savoye
- I.L. Ray-Coquard
Institutions
- Université Claude Bernard Lyon 1 (FR)
- SHOWA Medical University (JP)
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Université Paris Cité (FR)
- Cary Medical Center (US)
- Institut universitaire du cancer de Toulouse Oncopole (FR)
- Institut de Cancérologie de Lorraine (FR)
- Centre Léon Bérard (FR)
- Groupe Hospitalier Diaconesses Croix Saint-Simon (FR)
- Centre François Baclesse (FR)
- Centre de Recherche en Cancérologie de Lyon (FR)
- Institut Claudius Regaud (FR)
- Institut Jean Godinot (FR)
- SHOWA Medical University Hospital (JP)
- Institut Curie (FR)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-07-01
- DOI
- https://doi.org/10.1016/j.esmoop.2026.108053
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00